Lonza and Roche Enter into MycoTOOL Distribution Agreement for Rapid Mycoplasma Testing Solutions

April 11,2011 Basel, Switzerland

Lonza (SIX Swiss Exchange: LONN) and Roche (SWX: ROG) announced today that they have entered into a co-exclusive distribution agreement for the commercialization of Roche’s MycoTOOL® mycoplasma Polymerase Chain Reaction (PCR) assays. PCR is a commonly used molecular biology technique that amplifies a single copy of nucleic acid to generate millions of copies of a particular DNA sequence. MycoTOOL® utilizes PCR methodology for DNA target amplification and gel electrophoresis for same day detection, compared to standard methods that can take up to 28 days to achieve results.

MycoTOOL® detection kits are now available through Lonza for final release testing of pharmaceutical products, upon validation. Additionally, Lonza offers contract testing services using the MycoTOOL® test. The MycoTOOL® test is the first commercial NAT-based detection system that is used for mycoplasma biosafety testing of approved biological products.

Release testing with the MycoTOOL® PCR-test from Roche Custom Biotech, a part of Roche Applied Science, has been approved by the European Medicines Agency (EMA) for several pharmaceutical products. It is the first commercially available mycoplasma PCR test that is used to replace traditional mycoplasma tests (cell-dependent and cell-independent methods) during pharmaceutical production. Developed and manufactured within a regulated environment, the product design, production process, change control notification procedure, premium quality products, logistics, and fulfilment systems help ensure that the products retain their proven high quality.

Robert Yates, Head of Roche Applied Science, commented: “Lonza’s reputation for quality and customer care gives us confidence that MycoTOOL® will be placed in the right applications for customers who wish to perform rapid mycoplasma testing in-house, and for those who prefer to send their samples to a qualified outside laboratory for testing.”

“Roche and Lonza share the rare combination of being both consumers and providers of pharmaceutical quality control and diagnostics products. This internal integration of user and manufacturer helps ensure products align properly with user requirements and capabilities. The unique perspective of being a user of the very products you sell provides insight unattainable from the outside looking in. We are pleased to be working with Roche in bringing this advancement to our colleagues,” said Lukas Utiger, Head of Lonza’s Bioscience Division.

About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80,000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

About Lonza
Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Products and services span its customers’ needs from research to final product manufacture. It is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. In addition, Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Furthermore, the company is a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.

Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange. In 2010, the company had sales of CHF 2.680 billion. Further information can be found at www.lonza.com.

For further Information:

Lonza Group Ltd
Head of Corporate Communications
Dominik Werner
Tel +41 61 316 8798
Fax +41 61 316 9798
dominik.werner@lonza.com

Lonza Group Ltd
Investor Relations
Dirk Oehlers
Tel +41 61 316 85
Fax +41 61 316 9540
dirk.oehlers@lonza.com

Lonza Group Ltd
Media Relations
Melanie Disa
Tel +1 201 316 9413
Fax +1 201 696 3533
melanie.disa@lonza.com

Roche Diagnostics
Dr. Burkhard Ziebolz
Phone: +49 8856 604830
burkhard.ziebolz@roche.com

Browse All News
Bg